Handelsbanken Fonder
SYRE icon

Handelsbanken Fonder’s Spyre Therapeutics SYRE Stock Holding History

Handelsbanken Fonder’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.31M Buy
+26,000
New +$1.9M 0.01% 760

Other funds holding SYRE

Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
MAP
Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
EA
Ellsworth Advisors Hudson, Ohio $609M AUM 52.37% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
SO
STRS Ohio Columbus, Ohio $26.7B AUM 43.32% 1-Year Est. Return
Calamos Advisors
Calamos Advisors Naperville, Illinois $30.1B AUM 30.03% 1-Year Est. Return
AA
AlphaCentric Advisors San Juan, Puerto Rico $118M AUM

Handelsbanken Fonder's SYRE Position: Q2 2026 in Review

Handelsbanken Fonder opened a new position in Spyre Therapeutics (SYRE) in Q2 2026: 26,000 shares worth $2.31M. The stake represents 0.01% of the portfolio and ranks #760 among its holdings.

29 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Handelsbanken Fonder held 26,000 shares of Spyre Therapeutics worth $2.31M as of Q2 2026.
  • Spyre Therapeutics was a new Handelsbanken Fonder position in Q2 2026.
  • Spyre Therapeutics made up 0.01% of Handelsbanken Fonder's portfolio in Q2 2026, its #760 holding.
  • 29 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Handelsbanken Fonder's 13F filing for Q2 2026, filed 10 Jul 2026.